Literature DB >> 23801139

Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy.

Noriko Iwaki1, Yasuharu Sato, Katsuyoshi Takata, Eisei Kondo, Kyotaro Ohno, Mai Takeuchi, Yorihisa Orita, Shinji Nakao, Tadashi Yoshino.   

Abstract

Recently, atypical Castleman's disease (CD) was reported in Japan. This disease is considered as TAFRO syndrome or non-idiopathic plasmacytic lymphadenopathy (IPL), a constellation of clinical symptoms, namely, thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly without hyper-γ-globulinemia. Histopathologically, this disease is similar to hyaline vascular (HV)-type CD. Here, we present a 43-year-old Japanese woman meeting the clinical criteria of TAFRO syndrome who was successfully treated with combined corticosteroid therapy. She showed a rapidly progressive course of thrombocytopenia, systemic lymphadenopathy, fever, anasarca, and increase in acute inflammatory proteins without hyper-γ-globulinemia. Lymph node biopsy was performed and revealed HV-type CD without human herpes virus 8 infection, which was clinicopathologically compatible with non-IPL. The association of these atypical features with well-known multicentric Castleman's disease (MCD), namely, HV-type histology with systemic lymphadenopathy, marked thrombocytopenia even with a high level of interleukin-6, and increased acute inflammatory proteins without hyper-γ-globulinemia, suggests that TAFRO syndrome as presented in our case is a novel entity, which may have been diagnosed as MCD in the past. To define this novel entity more clearly and to demonstrate its etiology, further nationwide surveys of this syndrome and MCD are needed.

Entities:  

Mesh:

Year:  2013        PMID: 23801139     DOI: 10.3960/jslrt.53.87

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  24 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

2.  Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome.

Authors:  Tamami Fujiki; Suguru Hirasawa; Seishi Watanabe; Shunsuke Iwamoto; Ryoichi Ando
Journal:  CEN Case Rep       Date:  2017-03-07

3.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.

Authors:  Yasufumi Masaki; Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Norifumi Tsukamoto; Yasuhito Ishigaki; Nozomu Kurose; Makoto Ide; Jun Murakami; Kenji Nara; Hiroshi Yamamoto; Yoko Ozawa; Hidekazu Takahashi; Katsuhiro Miura; Tsutomu Miyauchi; Shinichirou Yoshida; Akihito Momoi; Nobuyasu Awano; Soichiro Ikushima; Yasunori Ohta; Natsue Furuta; Shino Fujimoto; Haruka Kawanami; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Shigeo Nakamura; Tomohiro Kinoshita; Sadao Aoki
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

4.  Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; David Wu; Aaron Goodman; Raymond Wong; Amy Chadburn; Sunita Nasta; Gordan Srkalovic; Sudipto Mukherjee; Heather Leitch; Raj Jayanthan; Simone Ferrero; Yasuharu Sato; Steve Schey; Angela Dispenzieri; Eric Oksenhendler; Pier Luigi Zinzani; Mary Jo Lechowicz; Christian Hoffmann; Naveen Pemmaraju; Adam Bagg; Alexander Fossa; Megan S Lim; Frits van Rhee
Journal:  Am J Hematol       Date:  2020-09-25       Impact factor: 13.265

Review 5.  Comprehensive analysis of 225 Castleman's diseases in the oral maxillofacial and neck region: a rare disease revisited.

Authors:  Xiaotong He; Qiong Wang; Yaping Wu; Jiaan Hu; Dongmiao Wang; Bin Qi; Wei Zhang; Yanling Wang; Jie Cheng
Journal:  Clin Oral Investig       Date:  2017-10-04       Impact factor: 3.573

6.  Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.

Authors:  Elizaveta Belyaeva; Ayelet Rubenstein; Sheila K Pierson; Delaney Dalldorf; Dale Frank; Megan S Lim; David C Fajgenbaum
Journal:  Hematol Oncol       Date:  2022-02-18       Impact factor: 4.850

7.  Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome.

Authors:  Shotaro Tatekawa; Koji Umemura; Ryuichi Fukuyama; Akio Kohno; Masafumi Taniwaki; Junya Kuroda; Yoshihisa Morishita
Journal:  Clin Case Rep       Date:  2015-04-22

8.  Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report.

Authors:  Silvia Tedesco; Laura Postacchini; Lucia Manfredi; Gaia Goteri; Michele M Luchetti; Antonella Festa; Armando Gabrielli; Giovanni Pomponio
Journal:  Exp Hematol Oncol       Date:  2015-01-14

Review 9.  Idiopathic multicentric Castleman's disease: a systematic literature review.

Authors:  Amy Y Liu; Christopher S Nabel; Brian S Finkelman; Jason R Ruth; Razelle Kurzrock; Frits van Rhee; Vera P Krymskaya; Dermot Kelleher; Arthur H Rubenstein; David C Fajgenbaum
Journal:  Lancet Haematol       Date:  2016-03-17       Impact factor: 18.959

10.  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

Authors:  Frits van Rhee; Peter Voorhees; Angela Dispenzieri; Alexander Fosså; Gordan Srkalovic; Makoto Ide; Nikhil Munshi; Stephen Schey; Matthew Streetly; Sheila K Pierson; Helen L Partridge; Sudipto Mukherjee; Dustin Shilling; Katie Stone; Amy Greenway; Jason Ruth; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Raj Jayanthan; Elaine S Jaffe; Heather Leitch; Naveen Pemmaraju; Amy Chadburn; Megan S Lim; Kojo S Elenitoba-Johnson; Vera Krymskaya; Aaron Goodman; Christian Hoffmann; Pier Luigi Zinzani; Simone Ferrero; Louis Terriou; Yasuharu Sato; David Simpson; Raymond Wong; Jean-Francois Rossi; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Eric Oksenhendler; David C Fajgenbaum
Journal:  Blood       Date:  2018-09-04       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.